Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Major pharmaceutical multinationals are looking to collaborate with Indian drug firms, leveraging their cost-efficient manufacturing capabilities, robust supply chains, and innovative research potential. 31 July 2024
The Russian government will be ready to significantly increase state procurements of drugs against hepatitis C in case of reduction price for them both by global drugmakers and Russian pharmaceutical companies. 31 July 2024
The Association of Foreign Pharmaceutical Manufacturers (AIPM), a trade association which unites more than 60 global drugmakers operating in the Russian market, has appealed to the country’s Federal Antimonopoly Service (FAS) to limit participation of a drug with the international non-proprietary name (INN) insulin glargine in tenders for public procurements in the Russian pharmaceutical market, according to recent statements by an official spokesman of the Association and some local media reports. 1 December 2020
At least one aspect of 2020 will be the same as any other year – pharma companies will end it with the traditional major data dump at the American Society of Hematology (ASH) Meeting and Exposition. 26 November 2020
German drugmaker Bayer has generally preferred in-licensing deals and other collaborations to multi-billion dollar acquisitions, so executives must have been highly impressed by what they saw of Asklepios BioPharmaceutical (AskBio) to spend $2 billion upfront on buying the US biotech, along with up to $2 billion more depending on certain milestones. 23 November 2020
The Russian government has ordered preparations for changes to the rules for registration of drugs in the Russian pharmaceutical market – in a move aimed to speed the launch of the drugs by three to five years, according to recent statements by an official spokesman of the government and some local media reports. 23 November 2020
Indian drug company, Laurus Labs is set to boost capacity with a $202 million infusion, underscoring the inherent advantages of Indian pharmaceutical firms that focus on molecules in diabetes, ophthalmology, and cardiovascular therapy. While three out of the top seven largest-selling drugs in the country are now anti-diabetes, the therapy is registering a robust double-digit growth year-on-year, reports The Pharma Letter’s India correspondent. 23 November 2020
Celgene-backed Chinese biotech Antengene had an initial public offering (IPO) in Hong Kong’s HKEX today (November 20). The Shanghai-based clinical -stage biotech, which develops small molecules and antibodies, raised HK$ 2.63 billion ($400 million) to speed up its further development. 20 November 2020
Two weeks after Americans voted in the presidential election, the losing candidate, Donald Trump, remains in denial over the outcome of the poll. 18 November 2020
US pharma giant Merck & Co, known as MSD outside the USA and Canada, has officially announced localization of grazoprevir/elbasvir as well as doravirine/lamivudine/tenofovir drugs in Russia at the facilities of its local partner Akrikhin Pharmaceuticals, according to the company. 17 November 2020
While much of the world’s focus is on what pharma can do to end the coronavirus pandemic, the rest of the industry is continuing its work ensuring innovative medicines reach those most in need. 17 November 2020
The high and rising cost of prescription drugs in the United States remains a concern for patients, physicians, payers, and policy makers. It is also a key priority for the US Food and Drug Administration, the Trump administration, and the Department of Health and Human Services (HHS). 16 November 2020
Brazil’s pharmaceutical industry is the largest in Latin America and currently the seventh biggest in the world though, according to projections from IQVIA, it could be in fifth position in 2023. 16 November 2020
The Indian pharmaceutical industry sees US President-elect Joe Biden’s proposed plan to expand Obamacare and reduce middlemen as positive steps. Looking to benefit from the Biden presidency on the back of an increased push for generic prescriptions and biosimilar strategy, Indian drugmakers expect the accent on localization to continue, reports The Pharma Letter’s India correspondent. 12 November 2020
As the coronavirus pandemic continues, the previously out-of-favor global biotech and life sciences sector is seeing significant investment and a reputational boost, writes Maxim Jacobs, managing partner and director of research at Edison Investment Research, in an Expert View. 4 November 2020
Given that the task of tackling the coronavirus pandemic is arguably the biggest – and certainly the highest profile – challenge that the pharmaceutical industry has faced this century, it is appropriate that the world’s largest pharma company is among the leaders of the race to find a vaccine. 3 November 2020
Indian drug companies have a new ally. The UAE government is all set to provide incentives, including financial contributions, and will help create a full ecosystem to support Indian pharmaceutical companies having strong research and development facilities, reports The Pharma Letter’s India correspondent. 2 November 2020
With an essential role in the health and well-being of societies, the pharmaceutical industry has long attracted robust levels of capital, matching the high cost of cutting edge R&D and the eventual returns on investment. 28 October 2020
If any single chart could tell the tale of Takeda’s global pharmaceutical ambitions, it would be one showing change in annual revenues. 27 October 2020
One of Russia’s largest plants for the production of active pharmaceutical ingredients (APIs) will soon be built in the St Petersburg region by the local enterprise Active Component JSC, a leading producer of pharmaceutical ingredients and drugs in the country, reports The Pharma Letter’s local correspondent. 26 October 2020
Jonathan Roses, counsel Wolf, Greenfield & Sacks and Matthew Birkett, partner, Hoffmann Eitle, provide an Expert View on general treatment of salt and polymorphic forms in the US Patent and Trademark Office, the European Patent Office and the courts. 23 October 2020